Post-Hysteroscopic Myomectomy Management with Provera
There is no established evidence-based protocol for routine Provera use after hysteroscopic myomectomy, and the dose you're describing (20mg TID = 60mg/day) is not standard for this indication. The FDA-approved dosing for abnormal uterine bleeding is 5-10mg daily for 5-10 days, not 20mg three times daily 1.
Provera Duration and Dosing Post-Myomectomy
Standard Approach
- If Provera is used post-hysteroscopic myomectomy, the evidence-supported regimen is 20mg daily (not TID) for 2 months 2
- This single study showed 50% amenorrhea rates and 100% reduction in menstrual flow when medroxyprogesterone 20mg daily was given for 2 months after endometrial resection 2
- No taper is described in the literature—simply discontinue after the 2-month course 2
Critical Caveat
The 20mg TID dosing you mentioned (60mg/day total) has no supporting evidence for post-myomectomy use. This appears to be off-label and potentially excessive. The acute bleeding protocol uses 20mg TID for only 7 days, then reduces to 20mg daily 3. Prolonged high-dose MPA carries risks including bone density loss and, with extended use beyond 4 years or in women >31 years, increased meningioma risk 4, 5.
Assessing Myomectomy Success
Timeline for Evaluation
- Symptom improvement should be evident by 2-3 months post-procedure 6
- Quality of life scores normalize within this timeframe across all myomectomy approaches 6
- Reassess at 3-6 month intervals to determine if symptoms are controlled 1
Success Criteria
The myomectomy was adequate if:
- Heavy menstrual bleeding is controlled (88.5% success rate expected) 7
- Bulk symptoms (pressure, bladder/bowel symptoms) resolve
- Anemia improves with normalized hemoglobin
- Patient reports acceptable quality of life
Consider myomectomy failure if:
- Persistent heavy menstrual bleeding despite 3-6 months post-op
- Recurrent or worsening bulk symptoms
- Ongoing anemia requiring transfusion
- Unacceptable quality of life impact
When to Consider Hysterectomy
Primary Indications
Move toward hysterectomy when:
- Failed myomectomy with persistent symptoms beyond 6 months
- Reintervention required—22% of hysteroscopic myomectomies cannot be completed in one session; 10% require reoperation 7
- Concurrent adenomyosis—these patients are "less likely to experience symptom relief from hysteroscopic myomectomy" and may need definitive surgery 6
- Significant intramural or subserosal fibroid burden causing symptoms—hysteroscopic approach only addresses submucosal fibroids 6
- Patient has completed childbearing and desires definitive treatment
Important Considerations
- Hysterectomy provides definitive resolution of all fibroid-related symptoms 6
- Even with ovarian preservation, hysterectomy carries increased cardiovascular and mood disorder risks, especially when performed at younger ages 6
- The 2024 ACR guidelines emphasize hysterectomy should be reserved for patients with no desire for future fertility 6
Practical Algorithm
At 2-3 months post-op:
- Assess bleeding pattern, bulk symptoms, hemoglobin
- If improved → continue observation, recheck at 6 months
- If unchanged/worse → imaging to assess residual/recurrent fibroids
At 6 months post-op:
- If symptoms controlled → annual follow-up
- If symptoms persist → counsel regarding hysterectomy vs. alternative treatments (UAE, MRgFUS)
- If concurrent adenomyosis identified → strongly consider hysterectomy as definitive option
Bottom line: The evidence does not support your proposed 20mg TID Provera regimen. If using MPA post-myomectomy, use 20mg daily for 2 months maximum, then stop without taper. Assess success at 3-6 months based on bleeding control and symptom resolution. Consider hysterectomy for failed myomectomy, concurrent adenomyosis, or when fertility is not desired and symptoms persist.